This trial will test whether Angiotensin II is effective and safe as a second-line vasopressor during liver transplantation.
1 Primary · 15 Secondary · Reporting Duration: 1 year
Experimental Treatment
Non-Treatment Group
50 Total Participants · 2 Treatment Groups
Primary Treatment: Angiotensin II · Has Placebo Group · Phase 2 & 3
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: